CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
Key Highlights
- ➤HHS interim policy covers six peptide bulk drug substances, including BPC-157 and TB-500
- ➤Policy shields qualifying compounders from enforcement under specified Section 503A conditions
- ➤CDT invested in Pep’d, citing expanded U.S. peptide-market opportunity
- ➤Covered peptides remain unapproved by the FDA under the interim policy
Expert Statements
James Bligh, Chief Executive Officer of CDT Equity
“CDT invested in Pep’d because we believe peptides represent an important and rapidly developing area of healthcare, and this week's announcement from HHS is an encouraging development for the sector. While the policy remains interim and the peptides covered by it have not been approved by the FDA, we believe this represents an important step in the evolution of the U.S. peptide market and a positive development for CDT’s investment in this hugely exciting sector.”
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for compounded peptides, which the Company believes is supportive of its strategic investment in Pep’d Inc., a U.S.-based peptide and telehealth company.
The U.S. Department of Health and Human Services (“HHS”) has announced an interim enforcement discretion policy covering six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 while the U.S. Food and Drug Administration (“FDA”) continues the rulemaking process concerning the Section 503A Bulks List.
Get started
Create a free account to read the full story.